RxDoctor Payments DataLook up a doctor →

Michael Tallarico, MD

Medical Oncology · Dyer, INNPI 1467773036

Payments from drug & device makers

$35,328in general payments, 2019–2025

Across 1,006 payments — averaging $35.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$9K
  • AstraZeneca$7K
  • Novartis$3K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Bristol Myers Squibb$1K
  • Merck$918
  • plus $13K from 54 others
$816in research payments, 2019–2025

Across 1 payment — averaging $815.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$816

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Daiichi Sankyo Inc.23$9,059
AstraZeneca(2 entities)76$6,516
Novartis71$2,611
E.r. Squibb & Sons, L.L.C.118$2,114
Bristol Myers Squibb80$1,060
Merck48$918
Pfizer62$895
Genentech USA, Inc.47$895
Astellas Pharma US Inc37$771
Amgen35$712
Johnson & Johnson(3 entities)26$654
Gilead(2 entities)29$583
Sanofi22$542
AbbVie25$536
Incyte Corporation24$499
Lilly USA, LLC19$425
GSK17$374
Regeneron Healthcare Solutions, Inc.13$290
Eisai Inc.15$287
Exelixis Inc.14$284
Seagen Inc.13$283
Pharmacyclics LLC, An Abbvie Company12$277
Sirtex Medical Inc2$241
Array Biopharma Inc14$234
Rigel Pharmaceuticals, Inc.11$228
Jazz Pharmaceuticals Inc.9$227
Takeda Pharmaceuticals U.S.A., Inc.10$218
Tesaro, Inc.7$205
Galvanize Therapeutics, Inc1$185
Sanofi-aventis U.S. LLC2$184
ADC Therapeutics America, Inc.4$176
Athenex Pharmaceutical Division, LLC1$175
Boehringer Ingelheim6$175
Bayer9$150
Janssen Scientific Affairs, LLC1$147
Tersera Therapeutics LLC6$147
Beigene USA, Inc.5$128
Intuitive Surgical1$126
Sumitomo Pharma America, Inc.4$101
EMD Serono, Inc.5$92
Sobi, Inc5$91
Coherus Oncology, Inc.5$86
Pharmaessentia USA Corporation4$78
Foundation Medicine, Inc.4$77
Deciphera Pharmaceuticals Inc.4$74
AVEO Pharmaceuticals, Inc.4$72
Blueprint Medicines Corporation3$66
Puma Biotechnology, Inc.3$55
Mirati Therapeutics, Inc.3$55
Adaptive Biotechnologies Corporation2$51
Ipsen Biopharmaceuticals, Inc2$46
Karyopharm Therapeutics Inc.2$44
Fresenius Kabi USA, LLC2$44
AMAG Pharmaceuticals, Inc.3$43
Epizyme, Inc.2$41
Sun Pharmaceutical Industries Inc.1$35
Geron Corporation1$35
Genmab U.S., Inc.2$35
Kyowa Kirin, Inc.2$35
Syndax Pharmaceuticals, Inc.1$34

How this compares

$35,328 in reported general payments places this provider in the 65th percentile of 67 medical oncology providers in Indiana.

See all medical oncology providers in Indiana →

Medicare billing

Part B allowed, 2024
$6,089,292
Medicare patients
971
Services billed
242,952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Dyer

See the full list for Indiana →

Where these figures come from

Is this you, or does something look wrong? →